Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(1 year, 11 months from now) | |
US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(2 years from now) | |
US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(2 years from now) | |
US9278182 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2026
(3 years from now) | |
US8926594 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2026
(3 years from now) | |
US7731686 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(3 years from now) | |
US10960155 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(3 years from now) | |
US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(4 years from now) | |
US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(4 years from now) | |
US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(4 years from now) | |
US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(5 years from now) | |
US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(5 years from now) | |
US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(5 years from now) | |
US8226610 | KALEO INC | Medical injector with compliance tracking and monitoring |
Apr, 2029
(6 years from now) | |
US8021344 | KALEO INC | Medicament delivery device configured to produce an audible output |
Nov, 2029
(6 years from now) | |
US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US10143972 | KALEO INC | Ultrafiltration membrane and a preparation method thereof |
May, 2031
(8 years from now) | |
US8627816 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2032
(9 years from now) | |
US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(11 years from now) | |
US10220158 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Mar, 2035
(12 years from now) |
Market Authorisation Date: 03 April, 2014
Treatment: Method for confirming dose delivery; Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone; Use of an auto injector to administer naloxone hcl; Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(1 year, 11 months from now) | |
US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(2 years from now) | |
US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(2 years from now) | |
US9278182 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2026
(3 years from now) | |
US8926594 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2026
(3 years from now) | |
US7731686 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(3 years from now) | |
US10960155 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(3 years from now) | |
US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(4 years from now) | |
US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(4 years from now) | |
US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(4 years from now) | |
US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(5 years from now) | |
US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(5 years from now) | |
US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(5 years from now) | |
US8226610 | KALEO INC | Medical injector with compliance tracking and monitoring |
Apr, 2029
(6 years from now) | |
US8021344 | KALEO INC | Medicament delivery device configured to produce an audible output |
Nov, 2029
(6 years from now) | |
US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US10143792 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
May, 2031
(8 years from now) | |
US8627816 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2032
(9 years from now) | |
US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(11 years from now) | |
US10220158 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Mar, 2035
(12 years from now) |
Market Authorisation Date: 19 October, 2016
Treatment: Method for confirming dose delivery; Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone; Use of an auto injector to administer naloxone hcl; Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10722510 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) | |
US11135155 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) | |
US10973814 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) |
Market Authorisation Date: 29 April, 2021
Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients
Dosage: SPRAY;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 9 months from now) | |
US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(1 year, 11 months from now) | |
US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(2 years from now) | |
US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(2 years from now) | |
US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(5 years from now) | |
US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US9814838 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(8 years from now) | |
US10143792 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
May, 2031
(8 years from now) |
Market Authorisation Date: 28 February, 2022
Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10085937 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
US9480644 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
US9775838 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
US9561177 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
US9707226 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
US9468747 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
US9211253 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) | |
US9629965 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(12 years from now) |
Market Authorisation Date: 18 November, 2015
Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Dosage: SPRAY, METERED;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11027072 | ADAMIS PHARMS CORP | Emergency devices |
May, 2039
(16 years from now) |
Market Authorisation Date: 15 October, 2021
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic